MedTrace Logo

A B-D-Glucan Driven Antifungal Stewardship Approach for Invasive Candidiasis

NCT03090334 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 34

Last updated 2024-08-28

No results posted yet for this study

Summary

This is a multicenter, prospective, open-label, randomized trial. Patients with severe abdominal condition developing severe sepsis or septic shock and receiving broad spectrum antibiotic and antifungal treatment will be randomized (1:1) to:

1. discontinue antifungal treatment based on negative (\<80 pg/ml) result of 1,3 beta-d-glucan performed on day 0,3,6 and 10
2. continue antifungal treatment according with attending physician's decision.

Conditions

  • Invasive Candidiases
  • Abdominal Infection

Interventions

DIAGNOSTIC_TEST

De-escalation

Antifungal therapy will be stopped according with BG results

Sponsors & Collaborators

  • University of Bologna

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-03-01
Primary Completion
2019-06-10
Completion
2019-06-10

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03090334 on ClinicalTrials.gov